Breakthroughs in therapies for NASH and remaining challenges

Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD

(2022) Elizabeth M. Brunt et al.   JOURNAL OF HEPATOLOGY

Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project

(2022) Arun J. Sanyal et al.   NATURE MEDICINE

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

(2022) Christopher L. Bowlus et al.   JOURNAL OF HEPATOLOGY

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.

(2021) Jörn M. Schattenberg et al.   JOURNAL OF HEPATOLOGY

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

(2021) Manal F. Abdelmalek et al.   Contemporary Clinical Trials

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

(2021) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial

(2021) Bettina Geidl-Flueck et al.   JOURNAL OF HEPATOLOGY

Therapeutic pipeline in nonalcoholic steatohepatitis

(2021) Raj Vuppalanchi et al.   Nature Reviews Gastroenterology & Hepatology

Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis

(2021) Andrea Dennis et al.   Frontiers in Endocrinology

Mechanisms and disease consequences of nonalcoholic fatty liver disease

(2021) Rohit Loomba et al.   CELL

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial

(2021) Samer Gawrieh et al.   HEPATOLOGY

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis

(2021) Emmanuel Anandraj Selvaraj et al.   JOURNAL OF HEPATOLOGY

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

(2021) Lone B Enebo et al.   LANCET

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

(2021) Rajaa Nahra et al.   DIABETES CARE

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

(2021) Rohit Loomba et al.   GASTROENTEROLOGY

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

(2021) Raj Vuppalanchi et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

(2021) Julio Rosenstock et al.   LANCET

PPAR‐γ‐induced Changes in Visceral Fat and Adiponectin Levels are Associated with Improvement of Steatohepatitis in Patients with NASH

(2021) Amalia Gastaldelli et al.   LIVER INTERNATIONAL

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

(2021) Stephen A. Harrison et al.   NATURE MEDICINE

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

(2021) Juan P. Frías et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity

(2021) Marco Arrese et al.   SEMINARS IN LIVER DISEASE

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

(2021) Martin Bossart et al.   Cell Metabolism

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

(2021) V. Ratziu et al.   NATURE MEDICINE

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

(2021) Sven M. Francque et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

(2021) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis

(2021) Rohit Loomba et al.   GASTROENTEROLOGY

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study

(2021) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease

(2021) Panu K. Luukkonen et al.   JOURNAL OF HEPATOLOGY

EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study

(2021) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease

(2020) Stefano Romeo et al.   Cell Metabolism

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

(2020) Rod S. Taylor et al.   GASTROENTEROLOGY

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

(2020) Vlad Ratziu et al.   HEPATOLOGY

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

(2020) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

(2020) Mark L. Hartman et al.   DIABETES CARE

Why do so many NASH trials fail?

(2020) Vlad Ratziu et al.   GASTROENTEROLOGY

Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis

(2020) Kimberly P. Newton et al.   HEPATOLOGY

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

(2020) Sander Lefere et al.   JOURNAL OF HEPATOLOGY

Real-World Burden of Nonalcoholic Steatohepatitis

(2020) Andreas Geier et al.   Clinical Gastroenterology and Hepatology

Utilization of a Deep Learning Algorithm for Microscope-Based Fatty Vacuole Quantification in a Fatty Liver Model in Mice

(2020) Yuval Ramot et al.   TOXICOLOGIC PATHOLOGY

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

(2020) Rohit Loomba et al.   Lancet Gastroenterology & Hepatology

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study

(2020) Stephen A Harrison et al.   Lancet Gastroenterology & Hepatology

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort

(2020) Tracey G Simon et al.   GUT

Nonalcoholic Steatohepatitis: Current Thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration

(2020) Frank A. Anania et al.   HEPATOLOGY

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

(2020) Rohit Loomba et al.   HEPATOLOGY

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis

(2020) Mohammad Shadab Siddiqui et al.   Clinical Gastroenterology and Hepatology

Diagnostic Accuracy of Non-Invasive Fibrosis Models to Detect Change in Fibrosis Stage

(2019) M. Shadab Siddiqui et al.   Clinical Gastroenterology and Hepatology

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

(2019) Arun J. Sanyal et al.   HEPATOLOGY

Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study

(2019) Debashis Haldar et al.   JOURNAL OF HEPATOLOGY

Past, present and future perspectives in nonalcoholic fatty liver disease

(2019) Arun J. Sanyal   Nature Reviews Gastroenterology & Hepatology

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis

(2019) Vlad Ratziu et al.   Contemporary Clinical Trials

Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy

(2019) Yan Wang et al.   GUT

Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand?

(2019) François Durand et al.   JOURNAL OF HEPATOLOGY

qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis

(2019) Feng Liu et al.   HEPATOLOGY

Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non‐alcoholic Fatty Liver Disease

(2019) Fasiha Kanwal et al.   HEPATOLOGY

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis

(2019) Fernando Bril et al.   JOURNAL OF HEPATOLOGY

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

(2019) Naga Chalasani et al.   GASTROENTEROLOGY

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

(2019) Guadalupe Garcia-Tsao et al.   JOURNAL OF HEPATOLOGY

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

(2018) Daniel J. Drucker   Cell Metabolism

Vibration-controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease

(2018) Mohammad S. Siddiqui et al.   Clinical Gastroenterology and Hepatology

Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

(2018) Stephen A. Harrison et al.   GASTROENTEROLOGY

Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation

(2018) Samar H Ibrahim et al.   GUT

Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data from a Large US Claims Database

(2018) Alina M. Allen et al.   HEPATOLOGY

Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population

(2018) Fredrik Åberg et al.   HEPATOLOGY

Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials

(2018) Cyrielle Caussy et al.   HEPATOLOGY

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

(2018) Scott L. Friedman et al.   HEPATOLOGY

PPARγ deacetylation dissociates thiazolidinedione’s metabolic benefits from its adverse effects

(2018) Michael J. Kraakman et al.   JOURNAL OF CLINICAL INVESTIGATION

Fructose and sugar: A major mediator of non-alcoholic fatty liver disease

(2018) Thomas Jensen et al.   JOURNAL OF HEPATOLOGY

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate

(2018) Benaïssa Boubia et al.   JOURNAL OF MEDICINAL CHEMISTRY

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

(2018) Philip Ambery et al.   LANCET

Deciphering the Roles of PPARγ in Adipocytes via Dynamic Change of Transcription Complex

(2018) Xinran Ma et al.   Frontiers in Endocrinology

Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease

(2018) Fasiha Kanwal et al.   GASTROENTEROLOGY

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

(2017) David Goldberg et al.   GASTROENTEROLOGY

Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis

(2017) Michael S. Middleton et al.   GASTROENTEROLOGY

Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease

(2017) Oscar Chávez-Talavera et al.   GASTROENTEROLOGY

High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men

(2017) Hannes Hagström et al.   GUT

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

(2017) Rohit Loomba et al.   HEPATOLOGY

Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis

(2017) Yan Wang et al.   HEPATOLOGY

Liver fibrosis scores predict liver disease mortality in the United States population

(2017) Aynur Unalp-Arida et al.   HEPATOLOGY

Distinct but complementary contributions of PPAR isotypes to energy homeostasis

(2017) Vanessa Dubois et al.   JOURNAL OF CLINICAL INVESTIGATION

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

(2017) Thomas Karlas et al.   JOURNAL OF HEPATOLOGY

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

(2017) Philipp Schwabl et al.   JOURNAL OF HEPATOLOGY

Liraglutide and Renal Outcomes in Type 2 Diabetes

(2017) Johannes F.E. Mann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

(2016) Amalia Gastaldelli et al.   HEPATOLOGY

Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort

(2016) Veronica Wendy Setiawan et al.   HEPATOLOGY

Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study

(2016) Arjola Bano et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Million Veteran Program: A mega-biobank to study genetic influences on health and disease

(2016) John Michael Gaziano et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study

(2016) Hannes Hagström et al.   JOURNAL OF HEPATOLOGY

Type 2 diabetes and risk of hospital admission or death for chronic liver diseases

(2016) Sarah H. Wild et al.   JOURNAL OF HEPATOLOGY

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

(2016) Jérôme Boursier et al.   JOURNAL OF HEPATOLOGY

Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease

(2016) Michael Pavlides et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

(2016) Len Verbeke et al.   Scientific Reports

The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats

(2015) Len Verbeke et al.   AMERICAN JOURNAL OF PATHOLOGY

Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States

(2015) Robert J. Wong et al.   GASTROENTEROLOGY

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

(2015) Arun J. Sanyal et al.   HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

(2014) L. Fedchuk et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes

(2014) Raymond E. Soccio et al.   Cell Metabolism

The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease

(2014) Rifaat Safadi et al.   Clinical Gastroenterology and Hepatology

Repair-Related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism

(2014) Brittany N. Bohinc et al.   ENDOCRINOLOGY

Roles for Chemokines in Liver Disease

(2014) Fabio Marra et al.   GASTROENTEROLOGY

Obesity and hepatocellular carcinoma: Hype and reality

(2014) Hashem B. El-Serag et al.   HEPATOLOGY

qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients

(2014) Shuoyu Xu et al.   JOURNAL OF HEPATOLOGY

Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist

(2013) Rebecca Taub et al.   ATHEROSCLEROSIS

A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials

(2013) H P Selker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease

(2013) Jennifer E. Lambert et al.   GASTROENTEROLOGY

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

(2013) Len Verbeke et al.   HEPATOLOGY

Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease

(2013) Rajarshi Banerjee et al.   JOURNAL OF HEPATOLOGY

Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins

(2013) Jerry R. Colca et al.   PLoS One

Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications

(2012) Kenneth Cusi   GASTROENTEROLOGY

Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: A prospective case-control study

(2012) Lei Xu et al.   JOURNAL OF HEPATOLOGY

Thiazolidinediones and PPARγ agonists: time for a reassessment

(2012) Bertrand Cariou et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Roles of PPARs in NAFLD: Potential therapeutic targets

(2011) Anne Tailleux et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Fatty Acid Bile Acid Conjugate Inhibits Hepatic Stearoyl Coenzyme A Desaturase and Is Non-atherogenic

(2010) Alicia Leikin-Frenkel et al.   ARCHIVES OF MEDICAL RESEARCH

Fibrosing NASH: On Being a Blind Man in a Dark Room Looking for a Black Cat (That Isn't There)

(2010) Michael R. Charlton   GASTROENTEROLOGY

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

(2010) Brent A. Neuschwander-Tetri et al.   HEPATOLOGY

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

(2010) Elizabeth M. Brunt et al.   HEPATOLOGY

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis

(2010) Judith Ertle et al.   INTERNATIONAL JOURNAL OF CANCER

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

(2008) Guruprasad P. Aithal et al.   GASTROENTEROLOGY

Liver biopsy

(2008) Don C. Rockey et al.   HEPATOLOGY

Impact of Fatty Liver Disease on Health Care Utilization and Costs in a General Population: A 5-Year Observation

(2007) Sebastian E. Baumeister et al.   GASTROENTEROLOGY